Esperion Announces Positive CHMP Opinion for the Marketing Authorisation Application for Bempedoic Acid for the Treatment of Hypercholesterolemia and Mixed Dyslipidemia
31 janv. 2020 07h01 HE
|
Esperion Therapeutics, Inc.
– Bempedoic Acid is an Oral, Once-Daily, Non-Statin Medicine that Lowers Bad Cholesterol with a First-in-Class Mechanism –– Positive CHMP Opinion is Based on the Completed Pivotal Phase 3...
Esperion to Present at the 38th Annual J.P. Morgan Healthcare Conference
07 janv. 2020 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Jan. 07, 2020 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that president and chief executive officer, Tim M. Mayleben, will present at the 38th Annual J.P. Morgan...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
22 nov. 2019 18h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 22, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that, on November 20, 2019, the Compensation Committee of Esperion’s Board of Directors granted 61,705...
Esperion Announces Publication in the Journal of the American Medical Association of Bempedoic Acid Phase 3 Study 2 Results
12 nov. 2019 11h05 HE
|
Esperion Therapeutics, Inc.
– Study 2 Demonstrated that Bempedoic Acid Significantly Lowered LDL-Cholesterol and Reduced hsCRP – – Over 52-Weeks, Overall Adverse Events in the Bempedoic Acid Treatment Arm were Comparable to...
Esperion to Participate in Upcoming Investor Conferences
07 nov. 2019 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 07, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR), today announced that the company will participate in fireside chats at the following conferences: Credit Suisse 28th...
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter Financial Results
06 nov. 2019 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today provided bempedoic acid franchise development program updates and financial results for the third quarter ended...
Esperion Announces Pooled Analyses from Phase 3 LDL-C Lowering Development Program of Bempedoic Acid to be Presented at the American Heart Association 2019 Scientific Sessions
04 nov. 2019 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) today announced that pooled analyses from four Phase 3 clinical trials of bempedoic acid will be presented at the American...
Esperion to Report Third Quarter 2019 Financial Results November 6, 2019
29 oct. 2019 07h30 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 29, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2019 financial results on November 6, 2019 before U.S. financial markets...
Bempedoic Acid Included in Top 10 Medical Innovations for 2020 List
25 oct. 2019 10h00 HE
|
Esperion Therapeutics, Inc.
ANN ARBOR, Mich., Oct. 25, 2019 (GLOBE NEWSWIRE) -- Esperion (NASDAQ:ESPR) announced that bempedoic acid was included in the “Top 10 Medical Innovations for 2020” at Cleveland Clinic’s 2019 Medical...
Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid / Ezetimibe Combination Tablet in Patients with Hypercholesterolemia and Type 2 Diabetes
29 août 2019 07h30 HE
|
Esperion Therapeutics, Inc.
— Bempedoic Acid / Ezetimibe Combination Tablet Achieved Robust 40% Placebo Corrected LDL-C Lowering —— Provided 25% hsCRP Reduction —— No Worsening of Glycemic Control —— Overall Adverse Events...